Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04764227
PHASE2

Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)

Sponsor: Fudan University

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate safety and 2-year local control rate for postoperative concurrent chemoradiotherapy for esophageal squamous cell carcinoma.

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

70

Start Date

2020-05-30

Completion Date

2027-03-30

Last Updated

2023-08-03

Healthy Volunteers

No

Interventions

DRUG

Paclitaxel

paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1, qw\*5

DRUG

Carboplatin

carboplatin AUC=2, ivgtt, d1, qw\*5

RADIATION

Radiotherapy

1.8Gy/d, d1-5/week, 28Fx

Locations (1)

Fudan University Shanghai Cancer Center

Shanghai, China